24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Actavis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
09:12
“Israeli startups have established a reputation for best-in-class innovation”
09:11
AI will cause trust issues during the 2024 election campaign, says Team8
09:11
“We really see the GenAI industry and the ecosystem changing in front of our eyes”
09:11
“I don't think AI will take everyone's job. I think it will change jobs.”
More stories
Buzz
Most popular
Daily
Weekly
1
Bill Ackman: "Israel needs support more than ever and I can help"
2
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
3
Wiz shareholders finalizing secondary deals worth hundreds of millions of dollars
4
Cyber decacorn Wiz in advanced negotiation to acquire Lacework for $150-200 million
5
Israel Innovation Authority launches new fund to catalyze $700 million investment in Israeli VCs
More news
Actavis
5 stories about Actavis
Allergan Says Teva Bears Sole Liability for Actavis' Actions
02.09.19
|
Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
The Crucial Piece of Information Teva Overlooked
24.12.17
|
Sophie Shulman
When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17
|
Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Allergan Sketches Road Show to Sell Teva Stake
14.08.17
|
Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
Allergan Can Now Sell 9.8% Teva Stake
03.08.17
|
Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended
Please ensure Javascript is enabled for purposes of
website accessibility